Piramal Pharma Share Price

Piramal Pharma Limited, with its operations headquartered in Mumbai, is a pharmaceutical company within the Indian healthcare and life sciences sector. The company operates across pharmaceutical production, contract development and manufacturing services, and complex hospital generics, serving regulated and semi-regulated global markets. Piramal Pharma share price on NSE and BSE is a reflection of how investors view the company compared to other players within the pharmaceutical sector and the company’s operational performance.

Piramal Pharma stock price is influenced ͏by factors like capacity utilisation, product pipeline progress, global healthcare demand, regulatory approvals and earnings visibility. Long-term strategic focus relating to the expansion of contract manufacturing, complex generics, and compliance with international regulatory standards drives market perception. These factors underpin how Piramal Pharma’s share price performs in different market conditions.

Piramal Pharma’s live share price offers updates on the last traded price, along with the bid and ask prices and the volume traded. These reflect activity in the underlying market, liquidity conditions, and investors’ reactions to corporate disclosures, regulatory updates, and sector-specific news. Keeping an eye on Piramal Pharma live price helps observe short-t͏erm stock volatility and how the stock is performing relative to ͏broader market ͏movements.

Also, monitoring Piramal Pharma share price today allows comparison with other listed pharmaceutical companies and relevant indices. This is useful for comparing the stock price performance within the pharmaceutical sector and in relation to the overall market.

Piramal Pharma Limited Fundamentals 

Piramal Pharma Limited Company Background

Piramal Pharma Limited is a global pharmaceutical company that operates through a diversified portfolio of products and services, supported by 17 development and manufacturing facilities across multiple geographies and a distribution network spanning more than 100 countries. The company functions through three core businesses: Piramal Pharma Solutions, an integrated Contract Development and Manufacturing Organization offering end-to-end solutions; Piramal Critical Care, which focuses on complex hospital generics; and the India Consumer Healthcare business, which markets a range of over-the-counter products in the domestic market. In addition to its core operations, Piramal Pharma Limited has an associate company, AbbVie Therapeutics India Private Limited, a joint venture with AbbVie Inc., which holds a strong position in the ophthalmology therapy segment. The company also maintains a minority investment in Yapan Bio Private Limited, reflecting its presence in emerging pharmaceutical areas. In October 2020, Piramal Pharma Limited received a 20% strategic growth investment from the Carlyle Group. The company is part of the Piramal Group, a global business conglomerate with interests across pharmaceuticals, financial services, and real estate, operating through offices in over 30 countries and supported by a workforce of more than 10,000 people representing 21 nationalities.

Piramal Pharma Limited Company Product Lines

Piramal Pharma Solutions (CDMO Services)

• Drug Discovery
• Antibody Drug Conjugates (ADCs)
• Drug Substance (APIs)
• Peptides
• Drug Product (Finished Dosage Forms)
• Vaccines and Biologics (through associate company Yapan Bio)
• Highly Potent APIs (HPAPIs)
• Sterile Fill/Finish
• Gene Therapies
• Clinical Trial Supplies

Piramal Critical Care

• Inhaled Anesthetics
• Intrathecal Therapy
• Injectable Anesthesia/Pain Management
• Injectables
• Specialty Therapeutics
• Plasma Volume Expander
• Pediatrics & Neonatal
• Animal Health
• Specialty Chemicals:

Piramal Consumer Healthcare

• Established Brands: Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, Tri-Activ
• Product Categories: Analgesics (Pain Management), Gastro-Intestinal (Antacid, Digestives, Gut Health), Hygiene, Skincare, Vitamins & Supplements (Multivitamins, Food Supplements), Women Care (Women Intimate Range), Baby Care & Kids’ Wellness, Oral Care, Respiratory (Cough & Congestion Relief)

Joint Venture: AbbVie Therapeutics India Private Limited (with AbbVie)

• Focus Area: Specialty Ophthalmology.
• Product Types: High-technology medications and devices for eye diseases.
• Therapeutic Areas: Glaucoma, Dry Eye, Ophthalmic Infections, Ophthalmic Inflammation.

Piramal Pharma Limited Company Revenue Model

Primary Revenue Streams (By Business Segment)

• Contract Development and Manufacturing Organization (CDMO): Revenue from providing end-to-end drug development and manufacturing services to global pharma and biotech clients. This includes APIs (active pharmaceutical ingredients), finished dosage forms, clinical and commercial manufacturing. CDMO is typically the largest revenue contributor for PPL.
• Complex Hospital Generics (CHG): Revenue from sales of complex hospital-focused generic medicines including inhalation anesthesia, injectable anesthesia, pain management, intrathecal therapy, and other hospital products sold in global markets.
• India Consumer Healthcare (ICH): Revenue from over-the-counter (OTC) consumer healthcare and wellness products marketed in India under multiple brands across categories such as analgesics, gastrointestinal, skincare, vitamins, supplements, baby care, women’s care, etc.

 Other Revenue-Related Sources

• Associate Income / Share of Profit from Associate Companies: PPL records revenue/profit share from its associate ventures like AbbVie Therapeutics India Private Limited (JV with AbbVie Inc.) and investment interests such as its minority stake in Yapan Bio Private Limited.
• Export Sales & Global Market Revenue: Revenue from international markets, especially North America, Europe and regulated markets, forms a significant portion of CDMO and CHG income. (Highlighted in performance commentary and annual reports.)

Strategic Revenue Enhancements

• Innovation-Led / On-Patent Manufacturing Within CDMO, a growing portion of revenue comes from innovation-related work and manufacturing of on-patent products, which generally command higher margins.
• Power Brands & Omnichannel Consumer Sales: In ICH, revenue growth is supported by power brands, omnichannel retail presence and e-commerce distribution

Piramal Pharma Limited Geographic Presence

Global Footprint

• Operations across development and manufacturing facilities located in India, North America, and Europe
• Commercial presence and product distribution in several countries
• Piramal Critical Care maintains a wide presence across the USA, Europe and more than 100 countries across the globe

Manufacturing & R&D Facilities

India

• Pithampur, Madhya Pradesh – Oral solid dosage manufacturing
• Rabale, Navi Mumbai – API research and development
• Ennore, Chennai – API process R&D and clinical supply manufacturing
• Digwal, Telangana – API and inhalation anaesthesia manufacturing
• Mahad, Maharashtra – Vitamins and mineral premix manufacturing
• Ahmedabad, Gujarat – Research and development operations
• Hyderabad, Telangana – Development and scientific services

North America

• Lexington, Kentucky, USA – Sterile development and manufacturing
• Riverview, Michigan, USA – High-potency API (HPAPI) manufacturing
• Sellersville, Pennsylvania, USA – Formulation development and manufacturing
• Bethlehem, Pennsylvania, USA – Anaesthesia manufacturing (Piramal Critical Care)
• Aurora, Canada – API development and manufacturing

Europe

• Grangemouth, Scotland, UK – Antibody-Drug Conjugate (ADC) manufacturing
• Morpeth, England, UK – API and formulation development

Corporate & Regional Offices

India

• Mumbai, Maharashtra – Corporate headquarters

Europe

• West Drayton, UK – Piramal Critical Care Ltd
• Verona, Italy – Piramal Critical Care Italia S.p.A.
• Hallbergmoos, Germany – Piramal Critical Care Deutschland GmbH
• Voorschoten, Netherlands – Piramal Critical Care B.V.

Other Regions

• Johannesburg, South Africa – Piramal Critical Care South Africa
• New South Wales, Australia – Piramal Critical Care Pty Ltd

Joint Ventures & Strategic Investments

• AbbVie Therapeutics India Private Limited
• Joint venture with AbbVie Inc.
• Focused on ophthalmology therapies
• Yapan Bio Private Limited
• Minority investment
• Focus on biologics and advanced therapeutics

Piramal Pharma Limited Leadership 

Some of the key leaders of Piramal Pharma Limited as of January 2026 are

• Nandini Piramal – Chairperson, Piramal Pharma Limited
• Peter DeYoung – Executive Director and Chief Executive Officer, Piramal Global Pharma
• Vivek Valsaraj – Executive Director and Chief Financial Officer, Piramal Pharma Limited
• S. Ramadorai – Independent Director
• Peter Stevenson – Independent Director
• Jairaj Purandare – Independent Director
• Vibha Paul Rishi – Independent Director
• Sridhar Gorthi – Independent Director
• Nathalie Leitch – Non-Executive Director
• Amit Jain – Non-Executive Director

Piramal Pharma Limited Key Milestones

• March 4, 2020 – Incorporated as a Public Limited Company and registered with the Registrar of Companies (RoC).
• 2020 – Established operations with end-to-end manufacturing capabilities across 17 global facilities and a distribution network spanning over 100 countries.
• 2020 – Structured operations across three business verticals: Piramal Pharma Solutions (CDMO), Piramal Critical Care (CHG), and India Consumer Healthcare (ICH).
• June 2020 – Acquired the pharmaceutical business from Piramal Enterprises Limited (PEL).
• October 2020 – Received growth equity investment from The Carlyle Group.
• October 2020 – Acquired 100% stake in Convergence Chemicals Private Limited (CCPL).
• 2020 – Announced expansion of antibody-drug conjugate (ADC) capabilities at the Grangemouth (UK) facility and drug substance capacity at the Riverview (USA) facility.
• 2021 – Acquired Hemmo Pharmaceuticals Private Limited (HPPL), expanding into peptide API development and manufacturing.
• October 7, 2021 – Composite Scheme of Arrangement approved for demerger and amalgamation involving PEL, CCPL, HPPL, and related entities.
• August 18, 2022 – Composite Scheme of Arrangement became effective.
• October 19, 2022 – Listed on BSE Limited and National Stock Exchange of India Limited (NSE) following the 4:1 share entitlement to PEL shareholders.
• 2022 – Acquired a minority stake in Yapan Bio Private Limited, an India-based CDMO focused on biologics and vaccines.
• FY 2023 – Launched 26 new products and 37 new SKUs.
• FY 2024 – Launched 27 new products and 24 new SKUs.
• FY 2025 – Launched 21 new products and 31 new SKUs.
• FY 2025 – Commenced manufacturing lines at Digwal, India, to supplement Sevoflurane production capacity at Bethlehem, USA.

Industry Perspective

India’s pharmaceutical industry is one of the world’s most dynamic and rapidly growing sectors, driven by robust demand for generic medicines, APIs, biologics, vaccines, and contract development and manufacturing services. India ranks third globally in pharmaceutical production by volume, supplying about 20 % of the world’s generic drugs and a significant share of global vaccines, making it a critical node in global healthcare supply chains.

The industry contributes around 1.7 % to India’s GDP and has expanded at a ~9–11 % CAGR over recent years, underpinned by supportive government policies, such as Production Linked Incentive schemes and liberal foreign investment norms. Market valuation estimates vary by source but indicate strong growth: one projection places the Indian pharmaceutical market at USD 61-66 billion in 2025, with forecasts ranging up to ~USD 120-130 billion by 2030, reflecting ~6-11 % CAGR over the decade. In niche segments like contract manufacturing and high-potency APIs, growth prospects are even stronger, with contract services markets expected to expand at double-digit CAGRs through 2030

Piramal Pharma Limited is positioned to benefit from the pharmaceutical industry’s growth through its diversified presence across CDMO services, complex hospital generics, and consumer healthcare. Its global manufacturing footprint, capabilities in high-value niches such as HPAPIs, biologics, and antibody-drug conjugates, and access to regulated markets enable alignment with rising outsourcing demand, export-led growth, and increasing global focus on quality-compliant pharmaceutical manufacturing.

Piramal Pharma Limited Stock Market Presence: Listings & Index Representation 

Piramal Pharma Limited was listed on the BSE (543635) and NSE (PPLPHARMA) following its corporate restructuring and demerger, marking its independent presence in India’s equity markets. Since listing, the company has remained actively traded on both exchanges, ensuring continuous price discovery and liquidity for market participants tracking pharmaceutical sector stocks.

Piramal Pharma Limited is part of several recognised indices, including Nifty 500, NIFTY Smallcap 100, Nifty Smallcap 250, and Nifty Smallcap 50. Inclusion in these indices places the company within the broader small-cap and diversified market universe, reflecting its market capitalisation and sector representation within India’s pharmaceutical landscape.

Piramal Pharma share price remains closely tracked due to its index presence, which brings visibility among institutional investors and index-linked funds. Listing on NSE and BSE supports consistent trading volumes, while index inclusion aligns the stock with benchmark performance tracking within the pharmaceutical and healthcare segments.

Piramal Pharma Limited Stock Performance and Share Price History

Piramal Pharma share price on NSE and BSE reflects its position as a pharmaceutical company operating across contract manufacturing and complex generics. Performance trends align with earnings movement, regulatory developments, capacity expansion, and sector-wide healthcare demand. Market participants often compare Piramal Pharma share price today with pharmaceutical peers and broader indices to assess relative positioning.

These factors appear across different timeframes in Piramal Pharma stock price movements. Earnings-linked announcements, regulatory approvals, and sector sentiment have influenced short-term price changes. Broader pharmaceutical sector trends have also played a role in shaping Piramal Pharma share price behaviour across market cycles.

Corporate actions and technical movements have contributed to fluctuations in Piramal Pharma stock price. While the company has not undergone frequent structural corporate actions, market re-rating following operational updates has resulted in visible short-term swings. These movements highlight how sector-specific factors can affect price action even without fundamental shifts.

Longer-term context emerges through Piramal Pharma share price 52-week high and low levels. The highest end-of-day price reached ₹293.36 on 6 November 2024, while the lowest end-of-day price touched ₹62.37 on 28 March 2023. These levels provide perspective on historical volatility and valuation ranges.

Piramal Pharma stock performance reflects the trading behaviour of a pharmaceutical company operating in a regulated global environment. Expansion into CDMO services and injectable therapies has shaped Piramal Pharma share price history, marked by sharp rallies and periods of consolidation.

Between 2022 and 2023, Piramal Pharma stock price experienced volatility, with 2022 delivering a decline of 39.66 percent amid restructuring adjustments and sector uncertainty. In 2023, the stock recovered with a 16.07 percent gain as operational clarity improved. The year 2024 saw a strong rise of 92.31 percent, supported by improved earnings visibility and sector momentum. In 2025, Piramal Pharma share price declined by 33.27 percent, reflecting broader small-cap corrections and profit-taking. Early 2026 shows a marginal decline of 2.12 percent.

Seasonality data highlights quarterly variation. In 2024, strong gains occurred in Q2, Q3, and Q4, resulting in annual returns above 90 percent. In contrast, 2025 recorded declines across all quarters, leading to a negative annual outcome. These patterns demonstrate how Piramal Pharma share price responds to both internal performance cycles and broader market conditions.

Despite sector disruptions, including pandemic-related supply chain challenges, Piramal Pharma stock price showed resilience over longer horizons. Over three years, the stock delivered a return of 47.49 percent, reflecting recovery from earlier lows and gradual operational stabilisation

Piramal Pharma Limited Investor Relevance and Portfolio Role 

Piramal Pharma holds relevance within healthcare-focused and small-cap portfolios, offering exposure to pharmaceutical manufacturing and contract development services. Its inclusion in indices such as Nifty 500 and NIFTY Smallcap 100 reflects its role within India’s listed pharmaceutical universe.

Piramal Pharma equity is held by a mix of domestic and global institutional investors. Key institutional holders include The Sri Krishna Trust, The Carlyle Group Inc., HDFC Asset Management Company Limited, V3 Designs LLP, PRL Realtors LLLP, East Bridge Capital Management LP, East Bridge Capital Master Fund I Ltd, The Vanguard Group, Life Insurance Corporation of India, and India hold Ltd.

Prominent mutual fund and global fund holders include HDFC Mutual Fund – HDFC Flexi Cap Fund, HDFC Mutual Fund – HDFC Focused 30 Fund, Vanguard Total International Stock ETF, Vanguard FTSE Emerging Markets ETF, Bandhan Small Cap Fund, Canara Robeco Small Cap Fund, iShares Core MSCI Emerging Markets ETF, Government Pension Fund Global, and Franklin India Opportunities Fund.

Beyond ownership, Piramal Pharma stock is monitored through technical indicators and derivatives data, where price trends, open interest, and volume patterns reflect market sentiment around earnings updates and regulatory developments. These indicators offer insight into short-term activity in Piramal Pharma stock price.

Piramal Pharma beta data shows varying volatility across timeframes. Daily one-month beta stands at 3.48, while the three-month daily range is 2.05. Weekly one-year beta is 1.37, easing to 0.783 over two years. Monthly two-year beta measures at 0.450. These figures indicate higher short-term sensitivity with moderated long-term volatility. Piramal Pharma stock price reflect these shifting volatility dynamics across periods.

Piramal Pharma Limited Sectoral Relevance and Peer Positioning

Piramal Pharma sector relevance stems from its presence in pharmaceutical manufacturing, CDMO services, and complex hospital generics, positioning it within India’s healthcare ecosystem. Peer comparisons with companies such as Sun Pharma, Dr Reddy’s Laboratories, Cipla, Aurobindo Pharma, and Lupin focus on manufacturing scale, regulatory compliance, global market exposure, and product complexity rather than short-term stock movements.

Piramal Pharma sectoral importance is also reflected in financial and market metrics that demonstrate its scale, stability, and systemic impact.

Piramal Pharma market cap stood at ₹219.89 billion as of January 2026. Market cap increased from ₹136.94 billion in 2022 to ₹183.93 billion in 2023, followed by a rise to ₹337.51 billion in 2024. In 2025, market cap declined to ₹230.24 billion before easing to ₹219.89 billion in 2026. These changes align with Piramal Pharma share price movements across cycles.

Piramal Pharma earnings growth highlights operational progress. Earnings rose from ₹2.95 billion in 2022 to ₹4.78 billion in 2023, followed by ₹7.99 billion in 2024. Earnings for 2025 (TTM) stood at ₹7.77 billion, reflecting a slight decline of 2.76 percent year-on-year.

Piramal Pharma EPS trends show variability. EPS stood at ₹5.80 in 2021, declining to ₹3.68 in 2022, followed by a negative ₹1.69 in 2023. In 2024, EPS improved to ₹0.15, with 2025 recording ₹0.73. These shifts correspond with restructuring phases and operational normalisation impacting Piramal Pharma stock price.

Piramal Pharma P/E ratio reflects earnings volatility. The P/E stood at 927 in 2024 before declining to 327 in 2025. As of January 2026, the P/E ratio measured at -142, reflecting accounting adjustments and earnings structure. These valuation metrics align with sector-specific regulatory and operational cycles influencing Piramal Pharma share price.

Summary

Piramal Pharma Limited’s diversified presence across CDMO services, complex hospital generics, and consumer healthcare positions it as a significant player in India’s pharmaceutical sector. With a global manufacturing footprint, strategic joint ventures, and a robust product portfolio, the company aligns with growing healthcare demand and outsourcing trends. Tracking Piramal Pharma share price provides insight into market sentiment, operational performance, and sector dynamics, reflecting both short-term volatility and long-term growth prospects in India’s dynamic pharmaceutical landscape.